{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:17:43Z","timestamp":1791299863685,"version":"4.1.0"},"reference-count":84,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T00:00:00Z","timestamp":1173052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p>LDL has been widely recognized as the major atherogenic lipoprotein and designated as the primary target for prevention of coronary heart disease (CHD); however, there is growing evidence that other triglyceride\u2010rich lipoproteins, such as very low\u2010density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) carry atherogenic potential as well. This led to the designation of non\u2010HDL cholesterol (HDL\u2010C) (LDL + IDL + VLDL) as a secondary target of treatment for hyperlipidaemia. As each one of LDL, IDL and VLDL particles carries only one apolipoprotein B\u2010100 (ApoB\u2010100) molecule, the total ApoB value represents the total number of potentially atherogenic lipoproteins, whereas non\u2010HDL\u2010C provides the cholesterol content of these same lipoproteins. Recent data from epidemiological, observational and interventional studies suggest that non\u2010HDL\u2010C, apolipoproteins ApoA1 and ApoB may improve CHD risk assessment by identifying more high\u2010risk individuals than the usual lipid profile alone. However, the targets for the optimal treatment of dyslipidaemia remain a subject of considerable debate. Further studies are needed to determine whether ApoB and ApoA1 are superior to conventional lipid parameters as predictors of cardiovascular disease or therapeutic targets of hyperlipidaemias. In this review, we summarize the current opinions on the use of ApoA1 and ApoB values as estimates of cardiovascular risk or as treatment goals in patients undergoing treatment for hyperlipidaemia.<\/jats:p>","DOI":"10.1111\/j.1463-1326.2007.00714.x","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T11:16:49Z","timestamp":1173093409000},"page":"271-278","source":"Crossref","is-referenced-by-count":72,"title":["The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment"],"prefix":"10.1111","volume":"10","author":[{"given":"M.","family":"Andrikoula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. F. W.","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01276.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)38425-X"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90520-W"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07098-2"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000035521.22199.C7"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.3.273"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-74-1-1"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200061022"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.363"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(98)90006-0"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00032-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.10.2474"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200012000-00008"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.10.2381"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.11.1413"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000038496.57570.06"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.1.8"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006193022503"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00031-9"},{"key":"e_1_2_5_22_2","first-page":"M8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann G","year":"1998","journal-title":"Eur Heart J"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1520-765X(03)90032-0"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.16.1886"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.69"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.15.1453"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.19.2517"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.5.477"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc1002.105136"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01638-1"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.10.5.668"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(93)90187-Y"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90856-T"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00406-2"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a060937"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.2.228"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000022850.59845.E0"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi003"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17018-9"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.08.017"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00580-9"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.11.2742"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000140629.65145.3c"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(02)00096-7"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095214"},{"key":"e_1_2_5_46_2","volume-title":"A comparison of Apolipoproteins A1 and B and lipid profiles for cardiovascular risk assessment in lipid clinic patients","author":"Andrikoula M","year":"2006"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.4.507"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.4.515"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.03.021"},{"key":"e_1_2_5_50_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/clinchem\/48.3.401","article-title":"Can measurement of apolipoprotein B replace the lipid profile in the follow\u2010up of patients with lipoprotein disorders?","volume":"48","author":"Durrington PN","year":"2002","journal-title":"Clin Chem"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.5.812"},{"key":"e_1_2_5_53_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/clinchem\/42.4.489","article-title":"Measurements of apolipoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinaemias","volume":"42","author":"Sniderman AD","year":"1996","journal-title":"Clin Chem"},{"key":"e_1_2_5_54_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International Federation of Clinical Chemistry standardisation project for measurements of apolipoprotein A\u2010I and B: IV. Comparability of apolipoprotein B values by use of international reference material","volume":"40","author":"Marcovina SM","year":"1994","journal-title":"Clin Chem"},{"key":"e_1_2_5_55_2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/clinchem\/43.8.1310","article-title":"Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision\u2010making","volume":"43","author":"Sniderman AD","year":"1997","journal-title":"Clin Chem"},{"key":"e_1_2_5_56_2","first-page":"44","article-title":"Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS\/TexCAPS trial","volume":"164","author":"Sniderman AD","year":"2001","journal-title":"CMAJ"},{"key":"e_1_2_5_57_2","first-page":"287","volume-title":"Handbook of Lipoprotein Testing","author":"Bhatnager D","year":"2000"},{"key":"e_1_2_5_58_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/clinchem\/44.8.1641","article-title":"Apolipoprotein B. and A\u2010I values in 147576 Swedish males and females standardized according to the World Health Organization\u2010International Federation of Clinical Chemistry First International Reference Materials","volume":"44","author":"Jungner I","year":"1998","journal-title":"Clin Chem"},{"key":"e_1_2_5_59_2","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/clinchem\/43.12.2364","article-title":"A\u2010I distributions in the United States, 1988\u20131991: results of the National Health and Nutrition Examination Survey III (NHANES III)","volume":"43","author":"Bachorik PS","year":"1997","journal-title":"Clin Chem"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2001.068"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02632-2"},{"key":"e_1_2_5_63_2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/clinchem\/37.8.1394","article-title":"Influence of intermediate\u2010density lipoproteins on the accuracy of the Friedewald formula","volume":"37","author":"Senti M","year":"1991","journal-title":"Clin Chem"},{"key":"e_1_2_5_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/36.1.15"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.11.2408"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00153-8"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01430-2"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890008998838"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.128049"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.129312"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00003-1"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02226-3"},{"key":"e_1_2_5_73_2","first-page":"292A","article-title":"ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolaemia","volume":"37","author":"Stein E","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_5_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2002.tb00099.x"},{"key":"e_1_2_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00005-5"},{"key":"e_1_2_5_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-200112000-00008"},{"key":"e_1_2_5_77_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.129312"},{"key":"e_1_2_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02632-2"},{"key":"e_1_2_5_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.12.1585"},{"key":"e_1_2_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00003-3"},{"key":"e_1_2_5_81_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2002.00988.x"},{"key":"e_1_2_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02847-3"},{"key":"e_1_2_5_83_2","doi-asserted-by":"publisher","DOI":"10.1161\/hq1001.096624"},{"key":"e_1_2_5_84_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.8.1177"},{"key":"e_1_2_5_85_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1998.00294.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2007.00714.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2007.00714.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:05:54Z","timestamp":1761887154000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2007.00714.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,5]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1463-1326.2007.00714.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2007.00714.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,5]]}}}